Omada Health shares jumped after the company made its public-market debut, propelled by Americans’ renewed focus on how ...

A consensus statement from the Society for Perioperative Assessment and Quality Improvement recommends patients should ...

Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for ...

A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, ...

Joie Armstrong knows that a home-cooked meal featuring whole foods is the best way to get her daily nutrients. She takes cues ...

Hydrocortisone oral solution (Khindivi) was approved as a replacement therapy for pediatric patients ages 5 years and up with ...

Coca-Cola (NYSE:KO) is not seeing the huge effect from GLP-1 usage that some investors feared when the drugs became more ...

GLP-1 drugs “alter taste perception” and "disrupt the perception of sweetness, bitterness, fatty foods and even mouthfeel”, a ...

While the medications may reduce diet, the best results will be achieved by building healthy habits alongside the drugs.

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

Omada Health, Inc. (NASDAQ:OMDA) closed its first day of trading at $23 per share on Friday, a 21% jump from the IPO price of $19 per share. On Thursday, Omada Health priced its initial public ...

GLP-1 drugs alter taste perception… and commonly disrupt the perception of sweetness, bitterness, fatty foods and even ...